RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q2 2024
Top Holdings78 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 10.1M | $1.4B | 18.2% | $92.75 | +47.04% | 23 qtrssince 2018-Q4 | Unchanged 0 |
VAXCYTE INC | 8.2M | $619.5M | 8.2% | $36.58 | +106.44% | 17 qtrssince 2020-Q2 | Unchanged 0 |
JANUX THERAPEUTICS INC | 9.2M | $383.9M | 5.1% | $24.54 | +70.67% | 13 qtrssince 2021-Q2 | Unchanged 0 |
Legend Biotech Corp. Sponsored ADR | 7.5M | $332.5M | 4.4% | $57.21 | -22.59% | 8 qtrssince 2022-Q3 | Increased 62 |
RHYTHM PHARMACEUTICALS INC | 6.1M | $249.8M | 3.3% | $25.49 | +61.11% | 23 qtrssince 2018-Q4 | Increased 64 |
BIOGEN IDEC INC | 982,139 | $227.7M | 3.0% | $223.60 | +3.68% | 10 qtrssince 2022-Q1 | Increased 72 |
CLIMB BIO INC | 31.4M | $223.4M | 3.0% | $11.35 | -37.33% | 12 qtrssince 2021-Q3 | Increased 85 |
RXSIGHT INC | 3.7M | $222.3M | 2.9% | $18.72 | +221.37% | 12 qtrssince 2021-Q3 | Increased 56 |
| 5.4M | $220.6M | 2.9% | $20.32 | — | 12 qtrssince 2021-Q3 | Increased 77 | |
DYNE THERAPEUTICS INC | 6M | $213.5M | 2.8% | $29.64 | +19.07% | 2 qtrssince 2024-Q1 | Increased 63 |
GERON CORP | 46.2M | $195.9M | 2.6% | $2.12 | +99.77% | 17 qtrssince 2020-Q2 | Unchanged 0 |
PEPGEN INC | 10.7M | $170.6M | 2.3% | $11.43 | +39.65% | 9 qtrssince 2022-Q2 | Unchanged 0 |
TYRA BIOSCIENCES INC | 10.4M | $166.6M | 2.2% | $16.75 | -4.56% | 12 qtrssince 2021-Q3 | Unchanged 0 |
EVOLENT HEALTH INC | 8.5M | $162.8M | 2.2% | $26.66 | -28.29% | 4 qtrssince 2023-Q3 | Increased 72 |
EDGEWISE THERAPEUTICS INC | 8.9M | $160.5M | 2.1% | $18.24 | -1.26% | 2 qtrssince 2024-Q1 | Unchanged 0 |
NewAmsterdam Pharma Company N.V. | 8.1M | $154.9M | 2.0% | $11.77 | +63.25% | 7 qtrssince 2022-Q4 | Increased 53 |
RECURSION PHARMACEUTICALS IN | 15.4M | $115.4M | 1.5% | $7.50 | 0.00% | 1 qtr | New 69 |
89BIO INC | 14.2M | $113.5M | 1.5% | — | — | 19 qtrssince 2019-Q4 | Increased 53 |
VERONA PHARMA PLC | 7.6M | $110.4M | 1.5% | — | — | 16 qtrssince 2020-Q3 | Increased 56 |
DAY ONE BIOPHARMACEUTICALS I | 7.9M | $108.5M | 1.4% | $18.87 | -26.98% | 13 qtrssince 2021-Q2 | Increased 48 |
RA CAPITAL MANAGEMENT, L.P. manages $7.6B across 78 positions as of Q2 2024. Top holdings: ASND (18.2%), PCVX (8.2%), JANX (5.1%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 11 new positions, 9 exits, 24 increased. Top move: CLYM (INCREASED, conviction 85). Portfolio: $7.6B across 78 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer